MA54542A - Compositions de sparsentan amorphe - Google Patents

Compositions de sparsentan amorphe

Info

Publication number
MA54542A
MA54542A MA054542A MA54542A MA54542A MA 54542 A MA54542 A MA 54542A MA 054542 A MA054542 A MA 054542A MA 54542 A MA54542 A MA 54542A MA 54542 A MA54542 A MA 54542A
Authority
MA
Morocco
Prior art keywords
sparsentan
amorphous
compositions
sparsentan compositions
amorphous sparsentan
Prior art date
Application number
MA054542A
Other languages
English (en)
Inventor
James Francis Hulvat
Dainius Macikenas
Kale Ruby
Xiangming Wu
Original Assignee
Travere Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Travere Therapeutics Inc filed Critical Travere Therapeutics Inc
Publication of MA54542A publication Critical patent/MA54542A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
MA054542A 2018-12-21 2019-12-20 Compositions de sparsentan amorphe MA54542A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862783947P 2018-12-21 2018-12-21

Publications (1)

Publication Number Publication Date
MA54542A true MA54542A (fr) 2021-10-27

Family

ID=69187971

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054542A MA54542A (fr) 2018-12-21 2019-12-20 Compositions de sparsentan amorphe

Country Status (12)

Country Link
US (1) US20220048900A1 (fr)
EP (1) EP3897834A1 (fr)
JP (1) JP2022514569A (fr)
KR (1) KR20210125994A (fr)
CN (1) CN114126712A (fr)
AU (1) AU2019404552A1 (fr)
BR (1) BR112021012226A2 (fr)
CA (1) CA3124127A1 (fr)
IL (1) IL284186A (fr)
MA (1) MA54542A (fr)
MX (1) MX2021007258A (fr)
WO (1) WO2020132594A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210081338A (ko) 2018-10-04 2021-07-01 트래버르 테라퓨틱스, 인코포레이티드 Iv형 콜라겐 질환의 치료를 위한 비페닐 설폰아미드 화합물
WO2022266370A1 (fr) 2021-06-17 2022-12-22 Aria Pharmaceuticals, Inc. Sparsentan pour le traitement de la fibrose pulmonaire idiopathique

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
JP2003520785A (ja) * 1999-12-15 2003-07-08 ブリストル−マイヤーズ スクイブ カンパニー アンジオテンシン・エンドセリン受容体二重拮抗薬としてのビフェニルスルホンアミド類
LT2732818T (lt) * 2009-03-31 2017-09-25 Ligand Pharmaceuticals Inc. Endotelino ir angiotenzino ii receptorių bifenilsulfonamido antagonistai, skirti glomerulosklerozės gydymui
WO2010135350A2 (fr) * 2009-05-20 2010-11-25 Pharmacopeia, Llc Composes intermediaires de biphenyle et procedes pour la preparation d'un double antagoniste de recepteur d'angiotensine ii et d'endotheline
KR102528435B1 (ko) * 2016-10-13 2023-05-03 트래비어 테라퓨틱스, 인코포레이티드 신장 질환 또는 장애의 치료를 위한 비페닐 설폰아미드 화합물

Also Published As

Publication number Publication date
AU2019404552A1 (en) 2021-07-15
CA3124127A1 (fr) 2020-06-25
MX2021007258A (es) 2021-08-16
US20220048900A1 (en) 2022-02-17
JP2022514569A (ja) 2022-02-14
EP3897834A1 (fr) 2021-10-27
KR20210125994A (ko) 2021-10-19
WO2020132594A1 (fr) 2020-06-25
IL284186A (en) 2021-08-31
CN114126712A (zh) 2022-03-01
BR112021012226A2 (pt) 2021-09-08

Similar Documents

Publication Publication Date Title
MA49519A (fr) Compositions agricoles
DK3697376T3 (da) Sammensætning
MA52413A (fr) Inhibiteurs de cd73
MA52546A (fr) Compositions ciblées
ES1243880Y (es) Cepillo de dientes
DK3810587T3 (da) Substituerede alkoxypyridinylindolsulfonamider
DK3473674T3 (da) Polypropylensammensætning
DK3890488T3 (da) Herbicide sammensætninger
MA50657A (fr) Formulations de niraparib
DK3819287T3 (da) Amorft tapentadolphosphat
IL284186A (en) Amorphous sparsantan preparations
MA50068A (fr) Formulations de copanlisib
DK3609464T3 (da) Xanthohumolbaserede sammensætninger
DK3528791T3 (da) Dispergible sammensætninger
DK3840596T3 (da) Sammensætning
ES1209313Y (es) Composicion liofilizada
DK3897130T3 (da) Agrokemisk sammensætning
DK3752258T3 (da) Trampolin
MA52129A (fr) Compositions
ES1230351Y (es) Dispositivo embellecedor de peldanos
IT201700104069A1 (it) Composizioni euglicemizzanti
ES1224186Y (es) Tuerca de empuje
DK3587968T3 (da) Fluidsystem
MA49925A (fr) Claie
CL2018001694S1 (es) Cepillo de dientes